Skip Navigation Links
 تاریخ های مهم 
 Pre Registered 
 برنامه همایش 
 Personal page 
                             دومین ويژه نامه همايش بهاره چشم پزشكي منتشر شد        شب بهاری چشم پزشکی با رحیم شهریاری       دومین همایش بهاره چشم پزشکی
Skip Navigation Links
        مکان برگزاری
        تاریخ های مهم
        ثبت نام
        ثبت نام شدگان
        برنامه همایش
        صفحه شخصی
        جستجوی سخنران
مقاله Abstract

Title: Design and structurally analysis of sFLT01-based novel tri-specific molecule with antiangiogenic activity.
Author(s): Hamid Latifi-navid, Zahra-Soheila Soheili, Mehdi Sadeghi, Shahram Samiei, Ehsan Ranaei Pirmardan
Presentation Type: Oral
Subject: Retina and Retinal Cell Biology
Presenting Author:
Name: Hamid Latifi Navid
Affiliation :(optional) National Institute of Genetic Engineering and Biotechnology, Tehran, Iran
E mail:
Mobile: 09375523135

Age-related macular degeneration (AMD) refers to the progressive degeneration of the macula that commonly occurs in people over 60 years of age. Experimental and clinical evidence has demonstrated that vascular endothelial growth factor (VEGF-A) plays a pivotal role in formation of choroidal neovascularization. Anti-VEGF agents represent the current standard of care for neovascular age-related macular degeneration (nAMD). There are however still a proportion of patients who do not respond to conventional therapy. One possible explanation for the high rate of non-responders is that an anti-VEGF monotherapy only blocks one pathway of pathological angiogenesis and other angiogenic factors may be responsible for the disease progression.


Therefore, the complimentary combinations of agents that inhibit alternative mechanisms of blood vessel formation may optimize inhibition of angiogenesis and improve clinical benefit for patients. sFLT01 is a dual targeting agent that neutralizes both VEGF and PlGF.


We designed a sFLT01-based novel tri-specific molecule that targets VEGF-A, PlGF and another angiogenic factor that is very important in the formation of new blood vessels. then we analyzed the secondary and tertiary structures of the tri-specific molecule.


It is believed that targeting several angiogenic pathways by sFLT01-based novel tri-specific molecule has potential as a next-generation antiangiogenic therapeutic for age-related macular degeneration.


Last News

  - دومین ويژه نامه همايش بهاره چشم پزشكي منتشر شد
  -  شب بهاری چشم پزشکی با رحیم شهریاری
  - دومین همایش بهاره چشم پزشکی